Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial With an Adaptive Design According to Response to Cemiplimab Monotherapy Using ctDNA and Subsequent Treatment With Chemotherapy (CT) and Cemiplimab or Cemiplimab Monotherapy in First Line Advanced NSCLC Patients

NCT06917573 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT06917573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06917573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial With an Adaptive Design According to Response to Cemiplimab Monotherapy Using ctDNA and Subsequent Treatment With Chemotherapy (CT) and Cemiplimab or Cemiplimab Monotherapy in First Line Advanced NSCLC Patients
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Recruiting
Start date
July 29, 2025
Completion date
December 30, 2031
Enrollment
63 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

lung diseases, non small cell lung cancer metastatic, respiratory tract neoplasms, stage iii non-small cell lung cancer, stage iv non-small cell lung cancer, thoracic neoplasms